To the Editor:

For decades, the human leukocyte antigen (HLA) complex has been considered the primary target of antibody-mediated rejection (AMR), and treatment strategies have mainly focused on anti-HLA antibodies. Recently, other antibodies potentially causing organ damage and loss have been discovered. Conclusive evidence on treatment options for these sub-types of AMR is still lacking. After an experience previously reported in this journal,[@B1] we describe a case of late-onset AMR, with mixed anti-HLA and anti-angiotensin II type 1 receptor (AT1R) antibodies, that was successfully treated with a multimodal approach, including the use of the proteasome inhibitor bortezomib.

A 39-year-old Caucasian man received a live-related renal transplant in 2007. The donor and the recipient were blood group compatible with a 5 ABDRDQ-HLA-antigen mismatch. Pre-transplant panel reactivity antibody and direct microcytotoxicity cross-match were negative. For baseline immunosuppression, the patient received basiliximab, tacrolimus, enteric-coated mycophenolate sodium, and steroids. Postopera-tive course and follow up were uneventful. Seven years after transplantation, the patient was hospitalized with worsening graft function and low calcineurin inhibitor levels ([Table 1](#T1){ref-type="table"}), reflecting occasional non-compliance with immunosuppressants. Antibody screening showed anti-HLA sensitization, with *de novo* donor-specific antibodies (DSAs) against B58 and DQ9, and high titers of anti-AT1R antibodies (\>50 U/L). Interestingly, both anti-HLA DSAs were unable to fix C1q, suggesting that anti-AT1R antibodies played a toxic role, in this specific setting. Histopathologic examination confirmed AMR. The patient received an initial multimodality treatment based on a combination of steroids, plasma exchange, and intravenous immunoglobulins. Then, bortezomib (Velcade®, Takeda, Osaka, Japan) was administered at 1.3 mg/m^2^ of body surface area, on days 1, 4, 8, and 11, to directly inhibit antibody production th-rough plasma cell depletion.[@B2] Following anti-rejection treatment, anti-HLA DSA and anti-AT1R antibodies promptly disappeared, and SCr stably decreased. One year later, the patient is doing fine, with stable graft function, no proteinuria, and undetectable DSA and anti-AT1R antibodies ([Table 1](#T1){ref-type="table"}).

Despite surgical innovations and novel immunosuppressive regimens, long-term kidney allograft survival has not significantly improved during last decades, since we are now losing organs mainly due to AMR.[@B3] Recently, in addition to anti-HLA antibodies, new antibodies have been discovered in transplant recipients experiencing rejection, supporting the hypothesis that anti-HLA antibodies may not be the only effectors of alloimmune humoral response. Among them, anti-AT1R antibodies seem to be particularly significant.

AT1R is the main receptor for angiotensin II. Anti-AT1R antibodies can mimic angiotensin II and trigger multiple autoreactive and alloreactive responses, eventually leading to cell damage, apoptosis, and hypertension due to allosteric activation of AT1R.[@B4] Anti-AT1R antibodies can act independently or synergistically with other effectors of the rejection pathway.[@B5]

Our patient experienced AMR seven years after transplantation due to non-compliance. An association between anti-HLA and anti-AT1R antibodies has been already described in under-immunosuppressed kidney transplant recipients.[@B5] *De novo* anti-AT1R antibodies have been also detected after episodes of allosensitization,[@B6] being consistently associated with rejection and poor graft and patient survivals.[@B7] However, testing for non-anti-HLA antibodies is not routinely performed, such that their real incidence and prevalence in the transplant population are basically unknown.[@B7]

What may trigger the development of anti-AT1R antibodies after transplantation is still under investigation. Several factors have been proposed: 1) genetic polymorphisms affecting the structure of AT1R extra-cellular domain; 2) genetic polymorphisms altering the geometric shape of the receptor; 3) antigenic exposure secondary to death perturbations; and 4) cell damage caused by alloimmune response, which modifies AT1R expression into the graft exposing previously hidden epitopes.[@B5]

Meanwhile, several therapeutic options have been proposed to treat early-onset anti-HLA AMR. Some combination strategies have shown good results in the short term, although no clear benefit of one specific regimen has been demonstrated, and long-term results are sub-optimal. Experience with late-onset non-anti-HLA AMR is even more limited.[@B8] Inhibition of B-cells and antibody production by administration of anti-CD20 monoclonal antibodies (e.g., rituximab) or proteasome inhibitors (e.g., bortezomib) may represent a promising option together with apheretic techniques and intravenous immunoglobulins.[@B9]

Optimal treatment of late-onset acute AMR is still a matter of debate. Reports on anti-AT1R AMR are anecdotal: some authors support the role of apheresis combined with intravenous normal human immunoglobulins, rituximab, and high-dose AT1R-blockers.[@B10] This journal has already published a first successful experience with bortezomib.[@B1] Our experience with a multimodality treatment, including bortezomib, confirms its efficiency in stably clearing not only anti-HLA but also anti-AT1R antibodies, halting renal function deterioration even in the longer term.

Further investigations are warranted to better address the role of proteasome inhibition in the setting of anti-HLA and non-anti-HLA AMR and to assess the contribution of bortezomib to overall efficacy.
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###### Clinical Parameters before, during, and after Bortezomib Administration
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  Parameters                      Normal range   Before rejection   Detection   Bortezomib administration   Day 90   Day 180   Day 365                 
  ------------------------------- -------------- ------------------ ----------- --------------------------- -------- --------- --------- ------ ------ ------
  SCr (mg/dL)                     0.6--1.2       1.1                1.89        1.6                         1.8      1.6       1.5       1.7    1.5    1.55
  eGFR (mL/min)                   \>90           80                 40          48                          42       48        53        47     53     50
  Proteinuria (mg/24 hr)          28--141        30                 94          \-                          \-       \-        0177      48     74     46
  WCC (cell×10^3^/µL)             4.8--10.8      \-                 7.0         8.2                         9.3      6.5       6.3       6.9    13.0   7.58
  NLR (\#)                        /              \-                 1.9         7.8                         4.6      2.1       1.9       1.3    3.9    2.0
  CRP (mg/L)                      \<0.5          \-                 \-          \-                          \-       0.03      0.03      \-     \-     \-
  Anti-HLA Class I Abs (%)        /              0                  11          0                           \-       \-        \-        0      0      0
  Anti-HLA Class II Abs (%)       /              0                  26          0                           \-       \-        \-        0      0      0
  DSA B58 (MFI)                   /              \-                 2755        \-                          \-       \-        \-        \-     \-     \-
  DSA DQ9 (MFI)                   /              \-                 3800        \-                          \-       \-        \-        \-     \-     \-
  Anti-AT1R Abs (U/l)             /              \-                 \>50        \-                          \-       \-        14        \-     0      0
  Prednisone (mg/day)             /              5                  5           20                          20       20        20        10     10     10
  Sodium mycophenolate (mg/day)   /              1440               1440        1440                        1440     1440      1440      1440   1440   1440
  Tacrolimus (mg/day)             /              3                  3           5                           5        5         5         6.5    5.5    5.5
  Tacrolimus C0 (ng/mL)           /              6.1                3.2         5.6                         6.8      4.4       5.2       8.3    5.7    4.6
  Diuresis (mL/24 hr)             /              \-                 3500        4500                        \-       3000      3300      3500   3300   4000

Abs, antibodies; AT1R, anti-angiotensin II type 1 receptor; C0, trough level; CRP, C-reactive protein; DSA, donor-specific antibodies; eGFR, estimated glomerular filtration rate; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; NLR, neutrophil-to-lymphocyte ratio; WCC, white cell count.
